arXiv preprint ·

Advancing Clinical Trial Outcome Prediction with Domain-Specific Large Language Models

Burak Bakkar, Hana Moalla, Mohamed Salem Jedidi, Haifa Ben Messaoud and Nicolas Lopez Carranza

Published
Source
arXiv preprint, posted before peer review
Original
Read it at arXiv
Topics
Artificial Intelligence

Abstract

Clinical trial failures are a major barrier to efficient drug development, incurring substantial costs and delaying patient access to effective therapies. Structured approaches such as the Hierarchical Interaction Network (HINT) predict trial outcomes by explicitly modelling interactions between drugs, diseases and protocols, but make limited use of the free text in trial registrations. We evaluate two domain-specific language models, BioBERT (108M parameters) and BioMistral (7B parameters), for phase-level outcome prediction on the TOP benchmark (12,477 trials), representing each trial as text built from ten ClinicalTrials.gov fields. We compare fine-tuning (full fine-tuning for BioBERT, low-rank adaptation for BioMistral) with probing, in which the pretrained model is frozen and only a lightweight classifier is trained on its embeddings. On the held-out test set of each phase, all four language-model variants achieved higher ROC-AUC (0.613--0.772) and PR-AUC (0.649--0.901) than the published HINT results, corresponding to relative PR-AUC gains of 10--20\%. F1 differences were small and mixed, and no model, including HINT, clearly exceeded the F1 of a trivial classifier that predicts success for every trial. Under the configurations tested, probing performed comparably to fine-tuning: fine-tuned models scored highest on ROC-AUC and PR-AUC in Phases I and II, and frozen BioMistral embeddings in Phase III (ROC-AUC 0.772; PR-AUC 0.901), although most differences between variants were below 0.03 and were not tested for significance. These results suggest that pretrained biomedical representations already encode signal relevant to trial outcome, and that probing is a computationally cheaper alternative to fine-tuning for this task.

The authors’ abstract, as arXiv lists it. arXiv’s listings, abstracts included, are free for anyone to reuse.

Read it on ReadSearch

Each opens after you create an account, and brings you back to this paper.

Already a reader? Sign in

All new papers in Artificial Intelligence

Get the few papers worth your time in Artificial Intelligence every morning.

ReadSearch reads the new papers in your field each day and brings you the few worth reading, each with its key finding in a sentence.

Papers belong to their authors and publishers; every page here links to the original. All research topics